Shares of Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) have received an average recommendation of “Buy” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $16.50.
RNN has been the subject of several analyst reports. ValuEngine raised shares of Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, November 2nd. Zacks Investment Research downgraded shares of Rexahn Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $19.50 price objective on shares of Rexahn Pharmaceuticals in a report on Monday, November 6th.
An institutional investor recently bought a new position in Rexahn Pharmaceuticals stock. Sabby Management LLC bought a new position in Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 246,946 shares of the company’s stock, valued at approximately $706,000. Sabby Management LLC owned approximately 0.87% of Rexahn Pharmaceuticals at the end of the most recent reporting period.
COPYRIGHT VIOLATION WARNING: This article was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://stocknewstimes.com/2018/02/11/analysts-set-rexahn-pharmaceuticals-inc-rnn-price-target-at-16-50.html.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.